secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001437749-23-008429
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic reports 2022 revenue up 21.9% to $2.93M; net loss narrows to $9.7M; COVID-19 vaccine trial dosing complete
--------------------------------------------------------------------------------

- Revenue $2.93M (+21.9% YoY); net loss $9.7M ($0.34/share) vs $13.1M ($0.47) in 2021.
- Cash $12.7M at year-end; received $1.27M from Alphazyme sale in Jan 2023; expects to fund ops into 2024.
- Phase 1 trial of DYAI-100 COVID-19 booster: dosing complete in low/high dose groups, no serious adverse events; full report H2 2023.
- Collaborations with Janssen, Phibro/Abic, global food ingredient company; Dapibus platform progress.
- Five peer-reviewed publications on C1-cell platform; new corporate website.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774923008429/0001437749-23-008429-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774923008429/dyai20221121_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-008429

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer